IMD-0560 |
رقم الكتالوجGC33306
One-Click Copy Product Info
|
IMD-0560 هو مثبط جديد لـ IκB kinase
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 439144-66-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IMD-0560 is a novel IκB kinase β inhibitor.
Pretreatment with IMD-0560 inhibits both IκBα degradation and p65 phosphorylation induced by TNFα. IMD-0560 also suppresses TNFα-induced transcriptional activity. Pretreatment with IMD-0560 strongly inhibits TNFα-induced cell invasion. Pretreatment with IMD-0560 suppresses MMP-9 activity by inhibiting MMP-9 expression[1].
The tumor size is reduced in the IMD-0560-treated groups in a dose-dependent manner, and no tumor is detected in some mice treated with 5 mg/kg IMD-0560. Zygoma destruction is significantly suppressed in the IMD-0560-treated groups compare to the control groups. Although the tumor size in the 5 mg/kg IMD-0560-treated group is smaller than that of the 3 mg/kg IMD-0560-treated group, the inhibitory effect of each treatment on zygoma destruction is similar[1].
[1]. Tada Y, et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma. Oncotarget. 2014 Dec 15;5(23):12317-30.
Cell experiment: | Cell migration is assessed in a modified chamber containing a gelatin-coated porous membrane. IMD-0560 is placed in the upper chamber 2 hrs prior to TNFα treatment, and TNFα is placed in the lower chamber at 10 ng/mL; then, the chamber is incubated for 24 hrs. Next, the cells attached to the upper surface of the membrane are scraped off, and the cells that migrate to the lower surface are fixed and stained with DAPI[1]. |
Animal experiment: | Sixty male mice, weighing approximately 20 g at 8 to 10 weeks of age are used. They are anesthetized using ether, and 0.1 mL of SCCVII in DMEM is injected into the left masseter region. The mice are randomly separated into six groups with similar average body weights. One week (early treatment: E) or 2 weeks (late treatment: L) after injection, the mice are injected between the left masseter region and the surface of the left mandibular bone with vehicle (50 μL of carboxymethyl-cellulose: CMC/mouse, n=10) or IMD-0560 (3 or 5 mg/kg/50 μL of CMC/mouse, n=10), 3 times per week for a total of 3 weeks (E) or 2 weeks (L). The tumor sizes are assessed using calipers, and the tumor volume is calculated. At the end of week 3, all surviving mice are euthanized, and the heads of the mice are fixed in 3.7% formaldehyde[1]. |
References: [1]. Tada Y, et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma. Oncotarget. 2014 Dec 15;5(23):12317-30. | |
| Cas No. | 439144-66-8 | SDF | |
| Canonical SMILES | O=C(C1=C(C=CC(Br)=C1)O)NC2=C(C=CC(C(F)(F)F)=C2)C(F)(F)F | ||
| Formula | C15H8BrF6NO2 | M.Wt | 428.12 |
| الذوبان | Ethanol : 50 mg/mL (116.79 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3358 mL | 11.679 mL | 23.3579 mL |
| 5 mM | 467.2 μL | 2.3358 mL | 4.6716 mL |
| 10 mM | 233.6 μL | 1.1679 mL | 2.3358 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)